GLP-1 analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Strontium-90 RTG cores were dumped behind, unlabelled and improperly dismantled, near the Soviet-built Enguri Dam. Three villagers from the nearby village of Lia were unknowingly exposed to it and injured; one of them died in May 2004 from the injuries sustained. The International Atomic Energy Agency led recovery operations and organized medical care. Two remaining RTG cores are yet to be found as of 2022.
Later works of James Prescott Joule, Rudolf Clausius and in particular Ludwig Boltzmann firmly established the kinetic theory of gases and brought attention to both the theories of Bernoulli and Waterston. The debate between proponents of energetics and atomism led Boltzmann to write a book in 1898, which endured criticism until his suicide in 1906. Albert Einstein in 1905 showed how kinetic theory applies to the Brownian motion of a fluid-suspended particle, which was confirmed in 1908 by Jean Perrin.
== Third round proper == The draw for the third round was made on 28 November 2022, consisting of the 20 winners from the previous round, all 20 members of the Premier League and the 24 EFL Championship clubs. The round included three teams from the fifth tier, the lowest-ranked teams remaining in the competition: Chesterfield, Boreham Wood, and Wrexham.
== Ergothioneine derivatives == Various derivatives of ergothioneine have been reported in the literature, such as S-methyl-ergothioneine or selenium-containing selenoneine. The latter is made using the same biosynthetic pathway as ergothioneine when selenocysteine is present.
Sources: en.wikipedia.org
These observations did not demonstrate whether cholesterol present in the animal body was due to synthesis or whether it had all actually come from vegetable food. The transformation of plant sterols into cholesterol within the body of an animal requires the sterol to be absorbable. This is the notion Schoenheimer investigated in his experiments. One of his experiments involved administering two different diets to a group of rabbits. Rabbits are sensitive to a diet which includes cholesterol, and their bodily responses particularly that of the aorta demonstrates a change that similarly resembles the Human atherosclerosis. In the experiment one diet involved a large amount of sito-sterol, which is a type of plant sterol. The other diet included cholesterol. The observations of the experiment indicated that Schoenheimer and his associates' theories that plant sterols were not absorbable were probable. Furthur studies were conducted and the findings concluded that plant sterols were non-absorbable, and therefore animals with plant only diets must synthesise the cholesterol necessary for their tissues as they do not receive absorbable cholesterol. During this period Schoenheimer became aware that cholesterol had an intermediary metabolism and that it was chemically inconvertable with other sterols. In one of his later experiments using sterols, he did discover a small percentage of one sterol, dihydrocholesterol in animal tissue. He investigated this finding using a dog which showed dihydrocholesterol was formed in the tissues.
=== Peripherally restricted === Peripherally acting μ-opioid receptor antagonists are used mainly in the treatment of opioid-induced constipation. These are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, they do not affect the analgesic effects of opioids within the central nervous system.
== Background == Enzymes are proteins that catalyze (i.e. accelerate) chemical reactions. They are natural catalysts and are ubiquitous, in plants, animals and microorganisms where they catalyze processes that are vital to living organisms. They are intimately involved in numerous biotechnological processes, such as cheese making, beer brewing and winemaking, that date back to the dawn of civilization. Recent advances in biotechnology, particularly in genetic and protein engineering, and genetics have provided the basis for the efficient development of enzymes with improved properties for established applications and novel, tailor-made enzymes for completely new applications where enzymes were not previously used. Today, enzymes are widely applied in many different industries and the number of applications continues to increase. Examples include food (baking, dairy products, starch conversion) and beverage (beer, wine, fruit and vegetable juices) processing, animal feed, textiles, pulp and paper, detergents, biosensors, cosmetics, health care and nutrition, waste water treatment, pharmaceutical and chemical manufacture and, more recently, biofuels such as biodiesel. The main driver for the widespread application of enzymes is their small environmental footprint. Many traditional chemical conversions used in various industries suffer from inherent drawbacks from both an economic and environmental viewpoint. Non-specific reactions can afford low product yields, copious amounts of waste and impure products.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.